At the recent American Diabetes Association's Scientific Sessions, Novo Nordisk announced that prescriptions for its Wegovy pill have surpassed 3 million since its U.S. launch five months ago. CEO Mike Doustdar highlighted this achievement despite competition from Eli Lilly, which has also seen increasing prescriptions for its Foundayo pill, although specific numbers were not disclosed.
The upcoming Medicare coverage, starting in July, will allow seniors to access GLP-1 drugs for weight loss at a cost of $50 per month, a significant reduction from previous out-of-pocket expenses.
Both companies are tailoring their marketing strategies to attract this demographic; Doustdar emphasizes Wegovy's additional health benefits, while Lilly's CEO Dave Ricks promotes the convenience of Foundayo's dosing schedule.
The competition is further intensified by the introduction of new drugs, with Lilly presenting promising data for its experimental drug retatrutide, which showed substantial weight loss results. Novo is also advancing its pipeline with CagriSema, although its efficacy has raised concerns among investors.
The outcome of this rivalry and the effectiveness of their marketing strategies could have substantial implications for their market positions and stock performance as they navigate the evolving landscape of obesity treatment and insurance coverage